Home

Intelligence

Services

Subscriptions

News

About Us

Sign In

 

Document Preview

Asset Purchase Agreement

 

Click "Add to Cart" button to purchase document. 
Documents are emailed immediately after purchase. 
You can also browse documents by
title, category, or company... or click here for help finding documents.

 

Title:

Asset Purchase Agreement

Entities:

Nabi Biopharmaceuticals

Date:

2007

Size:

Preview shows 65KB of 279KB total

Price:

$68

ID:

#3023197

 

 

► Purchase & Sale ► Purchase ► Asset Purchase Agreements
► Biotech & Drugs ► Biological Products

 

 

Start of Preview


EXECUTION VERSION

ASSET PURCHASE AGREEMENT

by and among

NABI BIOPHARMACEUTICALS,

BIOTEST PHARMACEUTICALS CORPORATION

and

BIOTEST AG

Dated as of September 11, 2007


TABLE OF CONTENTS

 

          Page
ARTICLE I DEFINITIONS    1
1.1   

Definitions.

   1
1.2   

Other Definitional Provisions.

   1
ARTICLE II PURCHASE AND SALE    2
2.1   

Purchase and Sale of Purchased Assets.

   2
2.2   

Excluded Assets.

   3
2.3   

Assumed Liabilities.

   4
2.4   

Excluded Liabilities.

   6
2.5   

Consent of Third Parties.

   7
2.6   

Purchase Price; Escrow.

   8
2.7   

Accounts Receivable.

   9
2.8   

Inventory.

   9
2.9   

Purchase Price Allocation.

   11
2.10   

No Set-Off.

   11
2.11   

Risk of Loss.

   12
ARTICLE III CLOSING    12
3.1   

Closing.

   12
3.2   

Transactions at Closing.

   12
ARTICLE IV REPRESENTATIONS AND WARRANTIES OF SELLER    16
4.1   

Organization.

   16
4.2   

Due Authorization.

   16
4.3   

Organizational Documents.

   17
4.4   

No Conflicts; Enforceability.

   17
4.5   

Title; Sufficiency.

   17
4.6   

Inventory; Equipment.

   18
4.7   

Intellectual Property.

   18
4.8   

Litigation.

   19
4.9   

Government Consents.

   20
4.10   

Third Party Consents.

   20
4.11   

Taxes.

   20
4.12   

Real Property.

   21
4.13   

Personal Property and Equipment.

   23
4.14   

Environmental, Safety and Health.

   23
4.15   

Employee Benefit Plans.

   24
4.16   

Compliance with Laws.

   26
4.17   

Regulatory Matters.

   26
4.18   

Contracts.

   27
4.19   

Financial Statements.

   29

 

i


4.20   

Accounts Receivable.

   30
4.21   

Absence of Certain Changes.

   30
4.22   

Brokers, Etc.

   31
4.23   

Insurance.

   31
4.24   

Compensation and Status of Employees.

   32
4.25   

Customers and Suppliers.

   33
4.26   

FDA Approval of the Boca Raton Facility.

   33
4.27   

Product Regulatory Status.

   34
4.28   

Return Policy.

   34
4.29   

Disclaimer.

   34
ARTICLE V REPRESENTATIONS AND WARRANTIES OF BUYER AND PARENT    35
5.1   

Organization.

   35
5.2   

Due Authorization.

   35
5.3   

No Conflicts; Enforceability.

   35
5.4   

Litigation.

   36
5.5   

Consents.

   36
5.6   

Financing.

   36
5.7   

Government Authorizations.

   36
5.8   

Brokers, Etc.

   37
5.9   

Independent Investigation.

   37
ARTICLE VI COVENANTS PRIOR TO CLOSING    37
6.1   

Access to Information.

   37
6.2   

Conduct of the Biologics SBU.

   37
6.3   

Required Notices, Approvals and Consents.

   40
6.4   

HSR Act; Other Antitrust Laws.

   40
6.5   

Proxy Statement; Seller Stockholders? Meeting.

   41
6.6   

No Solicitation; Acquisition Proposals.

   42
6.7   

Transition Activities.

   43
6.8   

Notifications; Updated Schedules.

   45
6.9   

Further Assurances; Further Documents.

   46
6.10   

Inventory.

   47
6.11   

Buyer Financing.

   47
ARTICLE VII CONDITIONS TO CLOSING    47
7.1   

Conditions Precedent to Obligations of Buyer and Seller.

   47
7.2   

Conditions Precedent to Buyer?s Obligations.

   47
7.3   

Conditions Precedent to Seller?s Obligations.

   48
ARTICLE VIII ADDITIONAL COVENANTS    49
8.1   

Confidentiality; Publicity.

   49
8.2   

Availability of Records.

   49
8.3   

Use of Trade or Service Marks; Name Change.

   50

 

ii


8.4   

Notification of Customers.

   50
8.5   

Products Returns, Rebate Charges and Wholesaler Charges.

   51
8.6   

Accounts Receivable.

   51
8.7   

Regulatory Matters.

   52
8.8   

Website Information.

   53
8.9   

Tax Matters.

   53
8.10   

Insurance.

   54
8.11   

Right of First Negotiation and First Refusal.

   54
ARTICLE IX EMPLOYEE MATTERS    54
9.1   

Employee Transfer.

   54
9.2   

Benefits.

   55
9.3   

Employee Information.

   56
ARTICLE X TERMINATION AND SURVIVAL    56
10.1   

Termination.

   56
10.2   

Procedure and Effect of Termination.

   58
ARTICLE XI INDEMNIFICATION    59
11.1   

Survival of Representations, Warranties and Covenants.

   59
11.2   

Indemnification by Seller.

   59
11.3   

Indemnification by Buyer.

   60
11.4   

Recoupment Against Escrow Agreement.

   61
11.5   

Calculation of Losses; Treatment of Indemnification Payments.

   61
11.6   

Termination of Indemnification.

   62
11.7   

Procedures.

   62
11.8   

Sole Remedy; No Additional Representations.

   64
11.9   

Limitations on Liability.

   64
ARTICLE XII MISCELLANEOUS    64
12.1   

Assignment; Binding Effect.

   64
12.2   

Expenses.

   65
12.3   

Notices.

   65
12.4   

Severability.

   66
12.5   

Entire Agreement.

   66
12.6   

No Third-Party Beneficiaries.

   66
12.7   

Waiver.

   67
12.8   

Governing Law; Arbitration.

   67
12.9   

Injunctive Relief.

   67
12.10   

Headings.

   68
12.11   

Counterparts.

   68
12.12   

Construction.

   68
12.13   

Parent Guaranty.

   68

 

iii


ANNEX AND EXHIBITS

 

Annex 1.1

   Definitions

Exhibit 1.1(a)

   Assignment and Assumption Agreement

Exhibit 1.1(b)

   Assignment of BSBU Intellectual Property

Exhibit 1.1(c)

   Bill of Sale

Exhibit 1.1(d)

   Buyer Registration Transfer Letter

Exhibit 1.1(e)

   Seller Registration Transfer Letter

Exhibit 6.7(b)

   Transition Services Agreement

Exhibit 6.7(c)

   Contract Manufacturing Agreement

Exhibit 8.3(b)

   Trademark License Agreement

Exhibit 8.11

   Right of First Refusal Agreement

 

iv


ASSET PURCHASE AGREEMENT

THIS ASSET PURCHASE AGREEMENT (this ?Agreement?), dated as of September 11, 2007 (the ?Execution Date?), is entered into by and among Nabi Biopharmaceuticals, a Delaware corporation (?Seller?), Biotest Pharmaceuticals Corporation, a Delaware corporation (?Buyer?), and Biotest AG, a company organized under the laws of Germany (?Parent?). Each of Seller, Buyer and Parent are sometimes referred to herein, individually, as ?Parties? and, collectively, as the ?Parties.? All capitalized terms used herein shall have the meanings specified in Annex 1.1 or elsewhere in this Agreement, as applicable.

RECITALS

WHEREAS, Seller owns certain assets relating to, used in or necessary for the development, manufacture, distribution, marketing and sale of biologics Products, and that together comprise the Biologics Strategic Business Unit (the ?Biologics SBU?) and certain other assets of Seller as described herein; and

WHEREAS, subject to the terms and conditions of this Agreement, Seller wishes to sell the Purchased Assets to Buyer, and Buyer wishes to purchase the Purchased Assets and assume the Assumed Liabilities from Seller.

NOW, THEREFORE, in consideration of the foregoing and the representations, warranties, covenants, agreements and provisions set forth herein and in the Other Agreements, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the Parties agree as follows:

ARTICLE I

DEFINITIONS

1.1 Definitions. Except as otherwise expressly provided, capitalized terms used in this Agreement shall have the meanings set forth in Annex 1.1.

1.2 Other Definitional Provisions.

(a) When a reference is made in this Agreement to an Article, Section, Exhibit, Schedule, Recital or Preamble, such reference is to an Article, Section, Exhibit, Schedule, Recital or Preamble of or to this Agreement unless otherwise indicated.

(b) The words ?hereof,? ?herein,? ?hereto? and ?hereunder? and words of similar import, when used in this Agreement, shall refer to this Agreement as a whole and not to any particular provision of this Agreement.

(c) The terms defined in the singular has a comparable meaning when used in the plural, and vice versa.

(d) Words of one gender include the other gender.


(e) References to a Person are also to its successors and permitted assigns.

(f) The term ?dollars? and ?$? means United States dollars.

(g) The word ?including? means ?including without limitation? and the words ?include? and ?includes? have corresponding meanings.

(h) The phrase ?delivered to Buyer? means either delivery to Buyer in paper or electronic form or by posting of the applicable material in the Data Room.

(i) The phrases ?arise after the Effective Time? and ?arising after the Effective Time? mean ?in respect of facts, circumstances or events occurring after the Effective Time.?

ARTICLE II

PURCHASE AND SALE

2.1 Purchase and Sale of Purchased Assets. At the Effective Time, on the terms and subject to the conditions hereof and in consideration of the Purchase Price to be paid to Seller by Buyer, Seller will sell, convey, transfer, assign and deliver to Buyer, free and clear of all Encumbrances other than the Permitted Encumbrances, and Buyer will purchase, take delivery of and acquire from Seller, all of Seller?s right, title and interest in and to the following Assets:

(a) all Assets of Seller relating to, used in or necessary for the operation of the Biologics SBU or the development, manufacture, distribution, marketing or sale of the Products, including the Assigned Contracts, the Inventory, the BSBU Prepaid Expenses, the BSBU Goodwill, the BSBU Licenses, the Registrations, the Promotional Materials, the Applicable Permits, the BSBU Equipment, the BSBU Personal Property Leases, the BSBU Records, the BSBU Intellectual Property, the Facilities, the Centers, the BSBU Real Property and the BSBU Real Property Leases;

(b) the Corporate Shared Services Assets;

(c) the vacant real property located at 5800 Park of Commerce Boulevard NW, Boca Raton, Florida, with parcel number 06434706030140000;

(d) any refund or credit of Taxes attributable to any Assumed Tax Liability; and

(e) (i) the Buyer Shared Use Assets not split or segregated pursuant to Section 6.7(d), (ii) to the extent split or segregated pursuant to Section 6.7(d), the split or segregated portion of any Buyer Shared Use Asset agreed to by the Parties to be owned or held by Buyer after the Effective Time, and (iii) to the extent split or segregated pursuant to Section 6.7(d), the split or segregated portion of any Seller Shared Use Asset agreed by the Parties to be owned or held by Buyer after the Effective Time;

(collectively, the ?Purchased Assets?), including (x) all goodwill relating thereto, (y) all rights in and to all warranties, guarantees, indemnities, causes of action and similar rights with respect


 

End of Preview

 

Home        Intelligence        Services        Subscriptions        News        About Us

Contact Us       Terms of Use       Resend Documents       Shopping Cart

Copyright © 2008 The Consus Group LLC